Wilms Tumor

Kidney model with a large smooth tumour bulging from its lower half
Wilms tumor (nephroblastoma) is a kidney cancer of young children that grows from embryonic kidney cells, usually found as a smooth, firm mass in the abdomen.
Infographic: healthy kidney, tumor inside the kidney, tumor through the capsule, spread to the lungs
The page describes staging that runs from a tumor limited to the kidney, through growth beyond its capsule, to spread to distant sites, most often the lungs.
Micrograph of Wilms tumor showing blue blastemal cells, pink stroma and small tubules
Under the microscope, classic Wilms tumor is triphasic: blastemal, stromal and epithelial cells that echo the developing kidney.

Wilms tumor, or nephroblastoma, is the most common primary renal malignancy in children and one of the great success stories of pediatric oncology — a disease that killed most affected children before the 1950s is now cured in more than 90% of patients through collaborative, protocol-driven treatment. Arising from embryonic kidney precursor cells, Wilms tumor teaches fundamental lessons about pediatric oncogenesis, the genetics of tumor suppressor genes, and the remarkable effectiveness of combining surgery, chemotherapy, and targeted radiotherapy in children. With approximately 500 new cases diagnosed annually in the United States, it remains the fourth most common pediatric malignancy overall.

Table of Contents

  1. Overview and Epidemiology
  2. Genetics and Predisposing Syndromes
  3. Pathology and Histology
  4. Clinical Presentation
  5. Diagnosis and Imaging
  6. Staging
  7. Treatment
  8. Prognosis and Survival
  9. Key Research Papers
  10. PubMed Topic Searches
  11. Connections
  12. Featured Videos

1. Overview and Epidemiology

Wilms tumor (nephroblastoma) is the most common primary malignant tumor of the kidney in children, accounting for approximately 85–90% of all pediatric renal tumors and roughly 6% of all childhood cancers in the United States. About 500 new cases are diagnosed annually in the United States, translating to an incidence of approximately 7.6 cases per million children under 15 years of age.

The peak age of diagnosis is 3 to 4 years. The tumor is rare in the first six months of life — when it does occur in infants this young, genetic syndromes are more likely to be involved — and it becomes uncommon after age 15. In the National Wilms Tumor Study registry (children registered 1969–1985), median age at diagnosis was 36.5 months for boys and 42.5 months for girls with a tumor in one kidney, and 23.5 and 30.5 months for boys and girls with tumors in both kidneys. Adult Wilms tumor exists but is rare, comprising less than 1% of adult renal malignancies, and generally carries a worse prognosis than the pediatric form.

Bilateral involvement occurs in approximately 5–10% of patients (Stage V disease). Bilateral tumors are more strongly associated with genetic predisposition syndromes, younger age at diagnosis, and nephrogenic rests. Managing bilateral Wilms tumor requires the additional imperative of preserving enough functional renal parenchyma to avoid dialysis dependence.

Sex distribution is roughly equal, with a slight female predominance in some series. There is a modest excess risk among children of African ancestry compared to Asian-ancestry children, with White and Black American children having similar rates. The disease occurs worldwide with relatively uniform incidence, unlike some adult cancers that show dramatic geographic variation tied to environmental exposures.

Before modern multimodality treatment, Wilms tumor was almost universally fatal. The National Wilms Tumor Study Group (NWTS), established in 1969 and succeeded by the Children's Oncology Group (COG), transformed outcomes through a series of landmark collaborative trials that progressively refined surgery, chemotherapy, and radiotherapy — achieving today's overall five-year survival exceeding 90%. A 2021 review in Nature Reviews Disease Primers states that cure is achievable in 90% of affected children, even those whose disease has spread, yet survival gaps remain within and between countries.

Back to Table of Contents

2. Genetics and Predisposing Syndromes

Wilms tumor arises through inactivation of tumor suppressor genes that regulate normal renal development. Approximately 10–15% of cases are associated with recognized genetic syndromes or constitutional mutations; the majority (~85%) are sporadic with no identifiable germline alteration at clinical evaluation, though somatic mutations accumulate during renal development.

WT1 Gene (11p13)

The WT1 gene on chromosome 11p13 encodes a zinc-finger transcription factor essential for normal kidney and gonadal development. Constitutional WT1 mutations or deletions underlie several overgrowth and genitourinary syndromes:

WT2 Locus (11p15) and Beckwith-Wiedemann Syndrome

A second Wilms tumor locus maps to chromosome 11p15.5 — the WT2 imprinting region that also controls the IGF2 (insulin-like growth factor 2) and H19 genes. Disruption of normal genomic imprinting at this locus produces Beckwith-Wiedemann syndrome (BWS), an overgrowth disorder characterized by:

In a 2016 meta-analysis of 1,370 people with BWS, 102 (7.4%) developed a tumor, with rates ranging from 2.5% to 22.8% depending on the molecular cause (PubMed PMID: 27372391; see Beckwith-Wiedemann Syndrome), with Wilms tumor being the most common (followed by hepatoblastoma and adrenocortical carcinoma). Children with BWS or isolated hemihypertrophy are enrolled in surveillance protocols with abdominal ultrasound every 3 months; a 2017 surveillance paper describes kidney ultrasound every 3 months through the seventh birthday, plus full abdominal ultrasound and blood alpha-fetoprotein every 3 months through the fourth birthday for hepatoblastoma (PubMed PMID: 28674120). A 2019 pooled analysis of published and unpublished cases found that screening until age 7 detects close to 95% of Wilms tumors in children with Beckwith-Wiedemann spectrum, and that children whose tumor was found by screening were diagnosed at lower stages than children who were not screened. Members of the American Association for Cancer Research Pediatric Cancer Working Group updated these surveillance guidelines, first published in 2017, in 2024.

Other Genetic Alterations

Back to Table of Contents

3. Pathology and Histology

Wilms tumor pathology is classified by histology into favorable and unfavorable categories — a distinction that has profound implications for treatment intensity and prognosis.

Favorable Histology (FH): The Classic Triphasic Pattern

The characteristic Wilms tumor is a triphasic tumor containing three tissue types that recapitulate normal metanephric development:

Not all tumors are equally triphasic; some are predominantly blastemal, others predominantly stromal or epithelial. Predominantly blastemal tumors in the SIOP (European) protocol after preoperative chemotherapy carry higher relapse risk and are treated as intermediate-risk.

Unfavorable Histology (UH): Anaplasia

Anaplasia is defined by three strict histologic criteria: (1) multipolar polyploid mitotic figures, (2) marked nuclear enlargement (nuclei at least 3 times the diameter of adjacent cells), and (3) nuclear hyperchromasia. In the fifth National Wilms Tumor Study (NWTS-5), anaplasia was found in 281 of 2,596 enrolled children (10.8%), but accounts for approximately 50% of Wilms tumor deaths — a dramatic overrepresentation driven by chemoresistance linked to TP53 mutations.

Nephrogenic Rests: The Precursor Lesions

Nephrogenic rests are foci of abnormally persistent embryonic kidney cells that normally involute after birth. They are found in approximately 1% of infant kidneys at autopsy but in approximately 35% of kidneys harboring unilateral Wilms tumor and in nearly all bilateral Wilms tumors. They are the direct precursors to Wilms tumor:

When nephrogenic rests are diffuse and bilateral, the condition is termed nephroblastomatosis — a finding that mandates surveillance and often preoperative chemotherapy to reduce bilateral tumor burden before nephron-sparing surgery.

Back to Table of Contents

4. Clinical Presentation

The overwhelming majority of Wilms tumor cases present as a smooth, firm, asymptomatic abdominal mass discovered incidentally — most commonly by a parent bathing or dressing the child, or by a clinician during a routine well-child visit. This presentation pattern reflects the tumor's typical encapsulation and the relatively large abdominal cavity in toddlers, which allows the tumor to grow to substantial size (often exceeding 500 grams) without causing symptoms.

Common Symptoms and Signs

Acquired von Willebrand Disease

An important and under-recognized association is acquired von Willebrand disease (aVWD), which occurs in approximately 8% of Wilms tumor patients. The tumor absorbs and degrades von Willebrand factor multimers, producing a coagulopathy that can cause significant intraoperative bleeding. Treatment teams check clotting before surgery (including a von Willebrand factor activity assay) and treat aVWD before the operation with desmopressin (DDAVP) or von Willebrand factor-containing concentrates.

Why Forceful Abdominal Examination Is a Known Hazard

Once Wilms tumor is suspected, repeated or forceful abdominal palpation is a recognized hazard. The tumor capsule, while usually intact at presentation, can be ruptured by aggressive examination — an event that upstages the patient to Stage III (requiring abdominal radiation) and significantly worsens prognosis. Pediatric teams examine such a child gently and teach staff caring for the child about this risk. Abdominal ultrasound, not repeated physical examination, is the usual next step for a child with an abdominal mass.

Back to Table of Contents

5. Diagnosis and Imaging

The diagnostic workup for a child with a suspected renal mass follows a logical sequence from rapid bedside assessment to detailed cross-sectional staging imaging. Tissue biopsy is generally deferred until after definitive nephrectomy in the North American (COG) approach, both to avoid upstaging from tumor spillage and because Wilms tumor diagnosis is usually confirmable by imaging alone.

Abdominal Ultrasound: First-Line Assessment

Abdominal ultrasound is the usual first test, done promptly, in any child with a palpable abdominal mass. Ultrasound provides rapid, radiation-free assessment of:

Computed Tomography Scan of Chest, Abdomen, and Pelvis

Contrast-enhanced computed tomography (CT) of the chest, abdomen, and pelvis is the standard staging modality in North America. Key findings include:

Magnetic Resonance Imaging

Magnetic resonance imaging of the abdomen is preferred over computed tomography in several circumstances: bilateral Wilms tumor (superior delineation of residual normal parenchyma for nephron-sparing planning), horseshoe kidney Wilms tumor (complex anatomy), intraspinal extension (rare), and in centers seeking to minimize radiation dose. Magnetic resonance imaging angiography delineates vascular anatomy and IVC thrombus with excellent detail.

Distinguishing Wilms Tumor from Neuroblastoma

This distinction is the most critical in pediatric abdominal oncology and can usually be made by imaging before pathology:

Urine VMA and HVA are commonly measured in children with a suspected renal or retroperitoneal mass to help exclude neuroblastoma before surgery.

Back to Table of Contents

6. Staging

The COG/NWTS staging system, used in North America, is a surgical-pathological staging system — meaning final stage is assigned after nephrectomy based on both intraoperative findings and pathologic assessment. This is distinct from the SIOP (European) system, which stages after preoperative chemotherapy. The COG stages are:

Intraoperative Staging Notes

Intraoperative findings critically determine final stage. Standard surgical protocol for Wilms nephrectomy includes:

Back to Table of Contents

7. Treatment

Treatment of Wilms tumor is governed by large collaborative group protocols — principally the Children's Oncology Group (COG) in North America and the Société Internationale d'Oncologie Pédiatrique (SIOP) in Europe and most of the rest of the world. The two approaches differ fundamentally in their sequencing of surgery and chemotherapy, but both achieve excellent results.

COG (North American) Approach: Surgery First

The standard COG approach for most patients is immediate nephrectomy followed by risk-stratified chemotherapy. This allows precise surgical-pathological staging (histology drives treatment), avoids the possibility of chemotherapy-induced histologic changes masking anaplasia, and provides tumor tissue for biologic studies.

Chemotherapy Regimens by Stage and Histology

In the Children's Oncology Group AREN0533 trial, 292 children with favorable-histology Wilms tumor that had spread only to the lungs were treated according to how their lung spots responded. In the 133 children whose spots disappeared after 6 weeks of three-drug chemotherapy, lung radiation was left out: their 4-year overall survival was 96.1%, though relapses and other events were more common than the trial expected (20.2% against 15%; 4-year event-free survival 79.5%). The 159 children whose spots remained (or whose tumor had lost parts of chromosomes 1p and 16q) received lung radiation and four cycles of cyclophosphamide and etoposide on top of the three drugs; their 4-year event-free survival was 88.5% and overall survival 95.4%. Across the whole trial, 4-year overall survival was 95.6%, up from 84.0% in NWTS-5.

Radiation Therapy

Radiation is reserved for Stage III+ favorable histology, Stage II+ anaplasia, and pulmonary metastases failing to resolve with chemotherapy. Radiation fields and doses are carefully tailored to minimize late effects — particularly vertebral growth asymmetry, hepatotoxicity (right lobe radiation), gonadal injury, and second malignancy risk — while maintaining locoregional control.

SIOP (European) Approach: Preoperative Chemotherapy

In the SIOP protocol, children aged 6 months and older with imaging-typical Wilms tumor receive 4 weeks of preoperative chemotherapy (actinomycin D + vincristine) before nephrectomy. Advantages of this approach include:

Disadvantages include: treatment of a small proportion of patients who ultimately have a non-Wilms renal tumor without a tissue diagnosis, and modification of tumor histology making anaplasia identification more challenging. Long-term survival outcomes are equivalent between COG and SIOP protocols.

Bilateral Wilms Tumor (Stage V): Nephron-Sparing Surgery

The management of Stage V disease prioritizes renal function preservation above all else. Standard approach:

AREN0534, the first prospective trial for children with tumors in both kidneys, enrolled 208 children, of whom 189 could be evaluated. After the three-drug chemotherapy, 84% had definitive surgery on at least one kidney by 12 weeks, and 39% kept parts of both kidneys. Four-year event-free survival was 82.1% and overall survival 94.9%; in the earlier NWTS-5 study, 4-year event-free survival for children with tumors in both kidneys had been 56%.

Back to Table of Contents

8. Prognosis and Survival

Wilms tumor is among the most curable of all pediatric solid tumors. The dramatic improvement in outcomes over the NWTS trial era — from approximately 30% survival in the 1960s to greater than 90% overall today — represents one of the landmark achievements of pediatric oncology. However, significant variation by histology and stage persists, and late treatment effects are an increasingly recognized challenge as survivors reach adulthood.

Survival by Stage and Histology

Newer Children's Oncology Group trials changed the outlook for anaplastic Wilms tumor. In AREN0321, 66 children with stage II–IV diffuse anaplasia received a regimen that added carboplatin to vincristine, doxorubicin, cyclophosphamide and etoposide plus radiation: 4-year overall survival was 73.7%, compared with 59.2% in NWTS-5, but doses had to be reduced partway through because of side effects, and 6% of the children died of treatment toxicity. In the pooled AREN0321 and AREN03B2 data on focal anaplasia, 4-year overall survival was 100% for stage I–II (21 children), 87.8% for stage III (17 children) and 85.7% for stage IV (7 children).

Relapse: Salvage and Prognosis

Approximately 15–20% of patients relapse after first-line therapy. Prognosis at relapse depends critically on initial treatment intensity:

Late Effects of Treatment

As more than 90% of children with Wilms tumor become long-term survivors, late effects of therapy have become a major focus of survivorship research:

Wilms tumor survivors are usually followed long term in a dedicated pediatric oncology survivorship clinic, with the frequency and content of monitoring set by the treatment received.

Back to Table of Contents

Key Research Papers

  1. Breslow N, Beckwith JB, Ciol M, Sharples K. Age distribution of Wilms' tumor: report from the National Wilms' Tumor Study. Cancer Res. 1988;48(6):1653–1657. Foundational epidemiologic dataset establishing peak age distribution and bilateral incidence. — PubMed PMID: 2830967
  2. Dome JS, Graf N, Geller JI, et al. Advances in Wilms tumor treatment and biology: progress through international collaboration. J Clin Oncol. 2015;33(27):2999–3007. Comprehensive review of NWTS/COG and SIOP protocol convergence and emerging biologic insights. — PubMed PMID: 26304882
  3. Spreafico F, Fernandez CV, Brok J, et al. Wilms tumour. Nat Rev Dis Primers. 2021;7(1):75. Primer covering epidemiology, genetics, staging, and global treatment approaches. — PubMed PMID: 34650095
  4. Treger TD, Chowdhury T, Pritchard-Jones K, Behjati S. The genetic changes of Wilms tumour. Nat Rev Nephrol. 2019;15(4):240–251. Detailed review of WT1, WTX, CTNNB1, SIX1/2, and miRNA pathway mutations with therapeutic implications. — PubMed PMID: 30705419
  5. Dix DB, Seibel NL, Chi YY, et al. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol. 2018;36(16):1564–1570. Practice-changing trial supporting omission of whole-lung radiation in Stage IV FH patients achieving complete pulmonary response. — PubMed PMID: 29659330
  6. Fukuzawa R, Heathcott RW, More HE, Reeve AE. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol. 2007;60(9):1013–1016. Demonstrates stepwise molecular progression from nephrogenic rest to Wilms tumor, validating the precursor model. — PubMed PMID: 17172473
  7. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23(29):7312–7321. Identifies 1p and 16q LOH as independent adverse prognostic markers in Stage I–II FH, leading to current COG risk-stratification incorporating these molecular markers. — PubMed PMID: 16129848
  8. Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol. 2006;24(15):2352–2358. Defines the differential outcomes of focal vs diffuse anaplasia and established the rationale for intensified therapy in diffuse anaplasia. — PubMed PMID: 16710034
  9. Pritchard-Jones K, Bergeron C, de Camargo B, et al. Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015;386(9999):1156–1164. Demonstrates non-inferiority of actinomycin D + vincristine without doxorubicin for intermediate-risk SIOP Stage II–III, reducing cardiotoxicity exposure. — PubMed PMID: 26164096
  10. Tournade MF, Com-Nougue C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Paediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol. 2001;19(2):488–500. Established the 4-week preoperative chemotherapy standard in the SIOP system and demonstrated equivalent outcomes with shorter preoperative duration. — PubMed PMID: 11208843
  11. Daw NC, Chi YY, Kalapurakal JA, et al. Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study. J Clin Oncol. 2020;38(14):1558–1568. — PubMed PMID: 32134700
  12. Armstrong AE, Daw NC, Renfro LA, et al. Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies. Cancer. 2025;131(2):e35713. — PubMed PMID: 39803937
  13. Ehrlich P, Chi YY, Chintagumpala MM, et al. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group. Ann Surg. 2017;266(3):470–478. — PubMed PMID: 28795993
  14. Mussa A, Duffy KA, Carli D, et al. The effectiveness of Wilms tumor screening in Beckwith-Wiedemann spectrum. J Cancer Res Clin Oncol. 2019;145(12):3115–3123. — PubMed PMID: 31583434
  15. Kalish JM, Becktell KD, Bougeard G, et al. Update on Surveillance for Wilms Tumor and Hepatoblastoma in Beckwith-Wiedemann Syndrome and Other Predisposition Syndromes. Clin Cancer Res. 2024;30(23):5260–5269. — PubMed PMID: 39320341

Back to Table of Contents

10. PubMed Topic Searches

  1. Wilms tumor nephroblastoma treatment
  2. Nephroblastoma genetics WT1 WT2
  3. Wilms tumor anaplasia prognosis
  4. Beckwith-Wiedemann syndrome Wilms tumor
  5. Bilateral Wilms tumor nephron-sparing surgery
  6. Wilms tumor late effects survivors
  7. Nephrogenic rests nephroblastomatosis
  8. WAGR syndrome WT1 deletion aniridia

Back to Table of Contents

11. Connections

Back to Table of Contents